ArticleBulletin of experimental biology and medicine2026
A New Modification of the Method for Assessing the Intraspecific Antagonistic Activity of Escherichia coli.
Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriocins, such as those produced by Escherichia coli, can be considered a promising alternative to antibiotics. The method of delayed antagonism based on the cross-streak test in our modification consisting in the use of nitrocellulose membranes, provides 80% reproducibility of detection of enrofloxacin-mediated induction of E. coli colicinogeny. Both bacteriostatic and bactericidal effects of colicins from various E. coli strains were demonstrated. No differences were found between autologous and heterologous action of enrofloxacin-induced colicinogeny. E. coli isolates from pig intestines differed in the spectrum of colicin activity and complemented each other, providing cooperative antagonism. Our results highlight the potential of bacteriocins as a promising approach for combating multidrug-resistant bacteria.
Indexed as
Identifiers
42507089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.